Teva Pharmaceutical Industries Ltd. $TEVA Stock Position Reduced by Parrish Capital LLC

Parrish Capital LLC lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 14.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 97,153 shares of the company’s stock after selling 16,584 shares during the quarter. Teva Pharmaceutical Industries accounts for about 2.6% of Parrish Capital LLC’s holdings, making the stock its 4th biggest position. Parrish Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $2,926,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TEVA. Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after purchasing an additional 7,255,083 shares in the last quarter. Wellington Management Group LLP increased its position in Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. Finally, Schroder Investment Management Group raised its stake in shares of Teva Pharmaceutical Industries by 261.1% during the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after purchasing an additional 5,370,253 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $34.55 on Friday. The stock has a 50-day simple moving average of $33.96 and a 200 day simple moving average of $32.55. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The stock has a market capitalization of $39.73 billion, a PE ratio of 25.98, a P/E/G ratio of 4.23 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on TEVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Finally, JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Buying and Selling

In other news, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the sale, the insider owned 80,760 shares in the company, valued at $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 465,931 shares of company stock valued at $16,332,989 in the last ninety days. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.